News 2019 

Novo Nordisk UK confirms no-deal Brexit plan

Gatwick, January 17 2019 – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is committed to ensuring patients’ insulin supply is unaffected in the event of a ‘no-deal’ Brexit - read more

 

 

 

This page is intended for UK consumer media, UK trade/medical media and members of the UK public

UK19NNG00001  January 2019